Meliane

Ethinylestradiol / Gestodene, the active ingredients in Meliane, constitute a combined oral contraceptive presented as a tablet for oral administration. The formulation works to prevent pregnancy by inhibiting ovulation and creating cervical mucus conditions unfavorable to fertilisation, and is intended for use by women of childbearing potential seeking reliable hormonal birth control.

GNH USA supplies Meliane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality for global contraceptive programmes.

Meliane, a combined oral contraceptive, is used in the hormonal regulation of reproductive function to prevent unintended pregnancy and manage certain menstrual disorders. - Prevention of pregnancy: provides reliable hormonal contraception for women of childbearing potential. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces cycle‑related discomfort. - Acne management: reduces androgen‑driven sebum production, improving mild to moderate acne in women.

Meliane may be associated with a range of adverse reactions, which are generally classified by frequency and severity. Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: temporary discomfort. - Headache: occasional throbbing pain. - Breakthrough bleeding: spotting between periods. - Weight gain: modest fluid retention. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: significant increase in blood pressure. - Hepatic adenoma: benign liver tumor. - Gallbladder disease: cholelithiasis or cholecystitis. - Severe allergic reaction: anaphylaxis or angioedema.

Before prescribing Meliane, clinicians should consider several precautionary measures to ensure patient safety. - Contraindications: avoid in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or active liver disease. - Smoking: do not prescribe to women over 35 who smoke, due to increased cardiovascular risk. - Cardiovascular risk: assess blood pressure and lipid profile before initiation. - Liver function: monitor hepatic enzymes in patients with pre‑existing liver conditions. - Medication adherence: advise consistent daily intake to maintain contraceptive efficacy. - Store at ambient temperature (below 25°C): keep in the original packaging, protect from moisture and light.

Meliane can interact with other medicines, altering its effectiveness or safety profile. Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive hormone levels. - Rifampicin and other potent antibiotics: decrease oral contraceptive efficacy. - St. John’s wort: herbal inducer that can lower hormone concentrations. - Protease inhibitors (e.g., ritonavir): may affect hormone metabolism. - Certain antiretroviral drugs: can compromise contraceptive reliability.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole, itraconazole): may increase hormone levels, raising side‑effect risk. - Diuretics: can exacerbate electrolyte disturbances and blood pressure changes. - Selective serotonin reuptake inhibitors: may increase risk of mood‑related side effects. - Antihypertensives: monitor blood pressure as combined hormones can affect vascular tone.